Product information and disease descriptionProduct descriptionProduct information
Co-prescribed/Concomitant therapies
1 evidence topic · 2 sources
Permitted concomitant medications and dose changes in the phase 2b trial
“Permitted concomitant medications for gMG included pyridostigmine, corticosteroids (equivalent to ≤40 mg of prednisone per day), azathioprine, mycophenolate mofetil and complement inhibitors, provided the dose was stable for at least 8 weeks before the first infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No dosing changes were allowed for concomitant MG-specific medications during the study, other than corticosteroids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The dose of corticosteroids was not permitted to be increased, but it could be tapered at the site investigator’s discretion after month 6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote